• Home
  • About Us
  • Calendar
  • Facebook
  • Twitter

Sleep Scholar

Sleep Scholar for Sleep Medicine Professionals

  • Calendar
  • About Us
You are here: Home / Uncategorized / Predictors of Response to a Nasal Expiratory Resistor Device and Its Potential Mechanisms of Action for Treatment of Obstructive Sleep Apnea

Predictors of Response to a Nasal Expiratory Resistor Device and Its Potential Mechanisms of Action for Treatment of Obstructive Sleep Apnea

April 3, 2011 by Randy Clare Leave a Comment

Amit V. Patel, M.D.1; Dennis Hwang, M.D.1; Maria J. Masdeu, M.D.2; Guo-Ming Chen1; David M. Rapoport, M.D.1; Indu Ayappa, Ph.D.1

1Division of Pulmonary, Critical Care and Sleep Medicine, NYU School of Medicine, New York, NY; 2Pulmonary Department, Corporacio Park Tauli, Universitat Autonoma Barcelona, Sabadell, Spain

Study Objective: A one-way nasal resistor has recently been shown to reduce sleep disordered breathing (SDB) in a subset of patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS). The purpose of this study was to examine characteristics predictive of therapeutic response to the device and provide pilot data as to its potential mechanisms of action.
Patients, Interventions, and Measurements: 20 subjects (15M/5F, age 54 ± 12 years, BMI 33.5 ± 5.6 kg/m2) with OSAHS underwent 3 nocturnal polysomnograms (NPSG) including diagnostic, therapeutic (with a Provent® nasal valve device), and CPAP. Additional measurements included intranasal pressures and PCO2, closing pressures (Pcrit), and awake lung volumes in different body positions.
Results: In 19/20 patients who slept with the device, RDI was significantly reduced with the nasal valve device compared to the diagnostic NPSG (27 ± 29/h vs 49 ± 28/h), with 50% of patients having an acceptable therapeutic response. Among demographic, lung volume, or diagnostic NPSG measures or markers of collapsibility, no significant predictors of therapeutic response were found. There was a suggestion that patients with position-dependent SDB (supine RDI > lateral RDI) were more likely to have an acceptable therapeutic response to the device. Successful elimination of SDB was associated with generation and maintenance of an elevated end expiratory pressure. No single definitive mechanism of action was elucidated.
Conclusions: The present study shows that the nasal valve device can alter SDB across the full spectrum of SDB severity. There was a suggestion that subjects with positional or milder SDB in the lateral position were those most likely to respond.
Keywords: Expiratory positive airway pressure, nasal valve, obstructive sleep apnea, sleep apnea therapy

Full Text:  http://www.ncbi.nlm.nih.gov/pubmed/21344051

 


Related posts:

  1. Compliance and Side Effects in Sleep Apnea Patients Treated With Nasal Continuous Positive Airway Pressure
  2. Interactions between obesity and obstructive sleep apnea: implications for treatment
  3. The Dental Decade of Obstructive Sleep Apnea Treatment
  4. Use of Flow–Volume Curves to Predict Oral Appliance Treatment Outcome in Obstructive Sleep Apnea
  5. Randomized Controlled Trial of Variable-Pressure Versus Fixed-Pressure Continuous Positive Airway Pressure (CPAP) Treatment for Patients with Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
Filed Under: Uncategorized

Speak Your Mind Cancel reply

*

*


+ 7 = eleven

Search

Editorial Board

Randy Clare
Managing Editor of SleepScholar and RespiratoryScholar
Dr. Steve Carstensen
Pankey Institute for Advanced Dental Education, American Academy of Dental Sleep Medicine.
Ruchir Patel MD
Founder & Medical Director at the Insomnia and Sleep Institute of Arizona.
Dr. John S. Viviano
AADSM Diplomate and member of various sleep organizations. Has lectured internationally on the treatment of Sleep-Disordered Breathing and the use of Acoustic Reflection.
Jeffroy Wyscarver
President, DDME Online, Sleep Lab Technology and Services for the Dental Community.
Claude Albertario
RPSGT, speaker, author and mentor in the field of sleep diagnostics with 25 yrs of management experience in one of New York's premier sleep centers.
Joseph Anderson
Co-Founder and Director of Education for Priority Health Education and Priority Scoring.
Todd Austin
Managed sleep labs and has 15 experience in sleep diagnostics and therapeutic systems. .
Marietta Bibbs
Sleep specialist and manager of Sleep and Neurodiagnostics at Morton Plant Mease Healthcare.
Bradley Eli DMD, MS
Director, San Diego Headache and Facial Pain Center / Sleep Treatment and Research Institute
Edward Grandi
Executive Director of the American Sleep Apnea Association.
Edward Michaelson MD
Board Certified in Pulmonary Medicine, Internal Medicine and Sleep Medicine
Ashley Truitt
Founder & Director of Dental Sleep Medicine Worldwide, Co-Founder of TPT Dental.

Upcoming Events

Georgia Association of Sleep Professionals
April 30, Atlanta, GA

No related posts.

Category: Uncategorized

Archives

  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • September 2010
  • August 2010

Random Posts

Introducting the new BW II PSG

Poor Sleep may Increase Risk of Breast Cancer

Home Testing for Sleep Apnea Not Inferior

Mandibular distraction osteogenesis in a skeletal Class II patient with obstructive sleep apnea

CPAP Tubing Overlooked No More

Return to top of page

Copyright © 2013 Sleep Scholar